Pharma and healthcare companies to face continued margin pressure: HDFC Securities

The Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the March quarter, according to a brokerage report by HDFC Securities. "We project sales/EBITDA growth of 11%/6% YoY for our coverage universe," the brokerage added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ys0ISVq
via IFTTT

Read More

Tiny hearts, big cardiac concern in India

A screening program in Raipur, Chhattisgarh, has found over 100 children with heart defects. Sixteen have undergone surgery, with more planned. This initiative, Project Dhadkan, aims to detect hidden heart risks early. Experts estimate many Indian children are born with such conditions. Early detection and treatment are crucial for normal lives. The program offers free screening and surgeries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KXrmtd8
via IFTTT

Read More

Sun Pharma closes in on Organon buy, gets set for $12 billion binding bid

Due diligence is complete, financing banks & advisors picked for biggest cross border pharma M&A by Indian pharma company. 2 other global suitors in fray.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U9kjgaM
via IFTTT

Read More

Iran conflict: Pharma supply chains may take months to recover

The recent ceasefire in the Iran conflict is a much-needed breath of fresh air for India's pharmaceutical sector, potentially rejuvenating exports. Nevertheless, industry specialists warn that it may take considerable time for supply chains to fully recover. Although raw material costs are projected to decrease slowly, West Asia remains a crucial market for Indian generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/76iNWdS
via IFTTT

Read More

Drugmaker Granules to tighten oversight after US FDA warning, executive says

The company, which is globally one of the largest paracetamol makers and a major player in the active pharmaceutical ‌ingredients market, derives ⁠a ⁠bulk of its revenue from the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/40fa8S5
via IFTTT

Read More

Govt ramps up feedstock supplies to pharma sector amid West Asia disruptions

India's government is boosting petrochemical feedstock for drug makers. This ensures essential medicines remain available as global supply chains face disruptions. Indian refiners are now supplying key inputs like propylene, ammonia, and methanol. Customs duties have also been reduced to ease costs. Domestic drug prices are stable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0FEKg3b
via IFTTT

Read More

Indian drugmaker Granules to tighten oversight after US FDA warning, exec says

Amid growing scrutiny from the U.S. FDA over documentation practices and contamination issues, Granules India is reinforcing its manufacturing framework. The company is turning to advanced digitization and automating record management to bolster data accuracy and compliance. By instituting these reforms, Granules India is proactively tackling regulatory challenges while ensuring excellence in product quality across all facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xRD2gdE
via IFTTT

Read More